{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:58:29Z","timestamp":1788897509503,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ijantimicag.2016.02.016","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T02:39:11Z","timestamp":1461983951000},"page":"439-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacokinetic\/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation"],"prefix":"10.1016","volume":"47","author":[{"given":"Gaoqi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyue","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/QCO.0b013e3283460e22","article-title":"Best practice in treating infants and children with proven, probable or suspected invasive fungal infections","volume":"24","author":"Katragkou","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/eri.09.19","article-title":"Diagnosis and treatment of aspergillosis in children","volume":"7","author":"Thomas","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0025","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10096-008-0543-1","article-title":"Pharmacokinetic\u2013pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies","volume":"27","author":"Nomura","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jac\/dkt369","article-title":"Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections","volume":"69","author":"Wang","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0035","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0040","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1128\/AAC.05010-11","article-title":"Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults","volume":"55","author":"Driscoll","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0045","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1128\/AAC.00702-11","article-title":"Population pharmacokinetics of voriconazole in adults","volume":"56","author":"Hope","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0050","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1128\/JCM.01230-13","article-title":"FUNGEMYCA Study Group. Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method","volume":"51","author":"Cant\u00f3n","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0055","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"48","author":"Espinel-Ingroff","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0060","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","article-title":"In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0065","series-title":"VFEND\u00ae (voriconazole) for injection, tablets and for oral suspension: LAB-0271-12","author":"Pfizer, Inc","year":"2005"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/dkh511","article-title":"The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe","volume":"55","author":"Masterton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0075","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2014.07.019","article-title":"Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia","volume":"44","author":"Doan","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0080","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/AAC.00032-15","article-title":"Achieving target voriconazole concentrations more accurately in children and adolescents","volume":"59","author":"Neely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0085","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0090","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0095","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0100","first-page":"306","article-title":"A pharmacokinetic\/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation","volume":"70","author":"Liao","year":"2015","journal-title":"Pharmazie"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00148581-200709050-00004","article-title":"Antifungal agents in neonates","volume":"9","author":"Almirante","year":"2007","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0110","series-title":"VFEND\u00ae package insert","author":"Pfizer, Inc","year":"2006"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0115","first-page":"124","article-title":"A review of clinical experience with newer antifungals in children","volume":"13","author":"Fallon","year":"2008","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.016_bib0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916300565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916300565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T18:24:46Z","timestamp":1536776686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916300565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0924857916300565"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.02.016","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic\/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}